Printer Friendly

MERIDIAN ANNOUNCES HIGHER FIRST QUARTER RESULTS

 MERIDIAN ANNOUNCES HIGHER FIRST QUARTER RESULTS
 CINCINNATI, Feb. 4 /PRNewswire/ -- Meridian Diagnostics, Inc.


(NASDAQ: KITS) announced today net sales and net earnings for the fiscal 1992 first quarter ended Dec. 31, 1991 of $2,970,000 and $286,000 ($.06 per share), respectively, as compared to net sales and net earnings of $2,254,000 and $136,000 ($.03 per share), respectively, during the same period of the prior fiscal year.
 Sales for the first quarter were up $716,000 or 32 percent, compared to the prior year's first quarter. Net earnings increased by $150,000 or 110 percent compared to the same period of the prior fiscal year.
 Commenting on the first quarter operating results, Jerry L. Ruyan, president, said, "We are pleased with the continuation of our sales and earnings growth through the first quarter of fiscal 1992. Gross profit margins increased to 65 percent from 62 percent primarily as a result of more favorable product mix and higher net sales." Ruyan went on to say, "Meridian's first quarter results were not influenced by the new products recently acquired in connection with the E-Z-EM, Inc., Texas BioResource Corp. or Disease Detection International, Inc. agreements. These eight new products were introduced to the market in late January 1992."
 The following table sets forth the comparative operating results of Meridian Diagnostics, Inc. for the three months ended Dec. 31, 1991 and 1990.
 MERIDIAN DIAGNOSTICS, INC.
 FIRST QUARTER RESULTS
 Three Months Ended
 December 31,
 1991 1990
 Net sales $2,970,000 $2,254,000
 Gross profit 1,925,000 1,400,000
 Operating income 433,000 161,000
 Earnings before income taxes 456,000 223,000
 Net earnings 286,000 136,000
 Earnings per common share $.06 $.03
 Weighted average number of
 shares outstanding 4,870,109 4,800,000
 Meridian Diagnostics, Inc. develops, manufactures and markets a variety of immunodiagnostic test kits, purified reagents such as antigens and monoclonal and polyclonal antibodies, and related diagnostic products. The company is a leader in the area of rapid diagnosis of infectious human diseases. All Meridian products are used outside the human body and require little or no special instrumentation or equipment. Domestic and international market segments consist of hospital, commercial and reference laboratories and physicians' offices. The company has a leading market position in fungal serology, and is the leader in parasite and bacterial collection, preservation and transportation systems. The company's shares are traded through NASDAQ/NMS (Symbol: KITS).
 -0- 2/4/92
 /CONTACT: Jerry L. Ruyan of Meridian Diagnostics, Inc., 513-271-3700/
 (KITS) CO: Meridian Diagnostics, Inc. ST: Ohio IN: MTC SU: ERN


KK -- CL010 -- 6768 02/04/92 13:59 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 4, 1992
Words:440
Previous Article:UNIQUE MOBILITY ANNOUNCES FISCAL 1991 RESULTS
Next Article:FORD ANNOUNCES SERVICE ACTIONS
Topics:


Related Articles
MERIDIAN REPORTS 61 PERCENT INCREASE IN FIRST QUARTER EARNINGS
MERIDIAN REPORTS 17 PERCENT INCREASE IN FIRST QUARTER EARNINGS
MERIDIAN INSURANCE GROUP ANNOUNCES 1993 SECOND QUARTER AND FIRST-HALF FINANCIAL RESULTS
MERIDIAN ANNOUNCES HIGHER SALES, OPERATING INCOME, AND EARNINGS FOR THE FIRST QUARTER
MERIDIAN INSURANCE GROUP ANNOUNCES CONTINUED NET INCOME GROWTH FOR 1993
MERIDIAN INSURANCE GROUP ANNOUNCES 1994 FIRST-QUARTER FINANCIAL RESULTS
MOST RECENT ANNUAL, QUARTERLY RESULTS POINT MERIDIAN BANCORP IN RIGHT DIRECTION; DIVIDEND INCREASE ANNOUNCED AT ANNUAL SHAREHOLDERS' MEETING
MERIDIAN INSURANCE GROUP REPORTS CONTINUED MOMENTUM IN 1995 FIRST QUARTER
Meridian Medical Technologies Reports Improved Core Operating Results
Meridian Medical Technologies Reports Quarterly Net Income of $0.20/Share

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters